Importing Wikidata short description: "Chemical compound"
|
Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. Added s2cid. | Use this tool. Report bugs. | #UCB_Gadget
|
||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
{{Short description|Chemical compound}} |
||
{{cs1 config|name-list-style=vanc}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
Line 49: | Line 50: | ||
}} |
}} |
||
'''UR-AK49''' is a drug used in scientific research which acts as a potent [[Receptor antagonist|antagonist]] for the [[Neuropeptide Y]] / [[Pancreatic polypeptide]] [[Receptor (biochemistry)|receptor]] [[Pancreatic polypeptide receptor 1|Y<sub>4</sub>]], and also as a [[partial agonist]] at the [[histamine]] receptors [[Histamine H1 receptor|H<sub>1</sub>]] and [[Histamine H2 receptor|H<sub>2</sub>]].<ref name="pmid16554355">{{cite journal |vauthors=Xie SX, Kraus A, Ghorai P, Ye QZ, Elz S, Buschauer A, Seifert R |title=N1-(3-cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a potent partial agonist for the human histamine H1- and H2-receptors |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=317 |issue=3 |pages=1262–1268 |date=June 2006 |pmid=16554355 |doi=10.1124/jpet.106.102897 |url=http://jpet.aspetjournals.org/cgi/reprint/317/3/1262.pdf }}</ref> UR-AK49 is a pure antagonist at Y<sub>4</sub> with no partial agonist effects, and although it is only slightly selective for Y<sub>4</sub> over the related [[Neuropeptide Y receptor Y1|Y<sub>1</sub>]] and [[Neuropeptide Y receptor Y5|Y<sub>5</sub>]] receptors, as the first non-peptide Y<sub>4</sub> antagonist developed UR-AK49 is expected to be useful in the study of this receptor and its role in the body.<ref name="pmid17885919">{{cite journal |vauthors=Ziemek R, Schneider E, Kraus A, Cabrele C, Beck-Sickinger AG, Bernhardt G, Buschauer A |title=Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence |journal=Journal of Receptor and Signal Transduction Research |volume=27 |issue=4 |pages=217–233 |year=2007 |pmid=17885919 |doi=10.1080/10799890701505206 }}</ref> |
'''UR-AK49''' is a drug used in scientific research which acts as a potent [[Receptor antagonist|antagonist]] for the [[Neuropeptide Y]] / [[Pancreatic polypeptide]] [[Receptor (biochemistry)|receptor]] [[Pancreatic polypeptide receptor 1|Y<sub>4</sub>]], and also as a [[partial agonist]] at the [[histamine]] receptors [[Histamine H1 receptor|H<sub>1</sub>]] and [[Histamine H2 receptor|H<sub>2</sub>]].<ref name="pmid16554355">{{cite journal |vauthors=Xie SX, Kraus A, Ghorai P, Ye QZ, Elz S, Buschauer A, Seifert R |title=N1-(3-cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a potent partial agonist for the human histamine H1- and H2-receptors |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=317 |issue=3 |pages=1262–1268 |date=June 2006 |pmid=16554355 |doi=10.1124/jpet.106.102897 |s2cid=26028129 |url=http://jpet.aspetjournals.org/cgi/reprint/317/3/1262.pdf }}</ref> UR-AK49 is a pure antagonist at Y<sub>4</sub> with no partial agonist effects, and although it is only slightly selective for Y<sub>4</sub> over the related [[Neuropeptide Y receptor Y1|Y<sub>1</sub>]] and [[Neuropeptide Y receptor Y5|Y<sub>5</sub>]] receptors, as the first non-peptide Y<sub>4</sub> antagonist developed UR-AK49 is expected to be useful in the study of this receptor and its role in the body.<ref name="pmid17885919">{{cite journal |vauthors=Ziemek R, Schneider E, Kraus A, Cabrele C, Beck-Sickinger AG, Bernhardt G, Buschauer A |title=Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence |journal=Journal of Receptor and Signal Transduction Research |volume=27 |issue=4 |pages=217–233 |year=2007 |pmid=17885919 |doi=10.1080/10799890701505206 |s2cid=26579625 }}</ref> |
||
== References == |
== References == |
![]() | |
Clinical data | |
---|---|
Other names | UR-AK49 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H27N5O |
Molar mass | 305.426 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
UR-AK49 is a drug used in scientific research which acts as a potent antagonist for the Neuropeptide Y / Pancreatic polypeptide receptor Y4, and also as a partial agonist at the histamine receptors H1 and H2.[1] UR-AK49 is a pure antagonist at Y4 with no partial agonist effects, and although it is only slightly selective for Y4 over the related Y1 and Y5 receptors, as the first non-peptide Y4 antagonist developed UR-AK49 is expected to be useful in the study of this receptor and its role in the body.[2]
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |